Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)

BACKGROUND: The use of imatinib mesylate is associated with a progression free survival of 41 months in first line treatment of metastatic or locally advanced gastrointestinal stromal tumors (GIST) and other studies approved that adjuvant imatinib treatment improves the recurrence-free survival in p...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidel, Christoph, Fenner, Martin, Länger, Florian, Bantel, Heike, Ganser, Arnold, Grünwald, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404905/
https://www.ncbi.nlm.nih.gov/pubmed/22612794
http://dx.doi.org/10.1186/1471-2407-12-186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404905/
https://www.ncbi.nlm.nih.gov/pubmed/22612794
http://dx.doi.org/10.1186/1471-2407-12-186

Ejemplares similares